What the FDA labels say about taking them together
Esomeprazole and mycophenolate mofetil
Esomeprazole's FDA label of March 19, 2024 names mycophenolate mofetil in its drug interactions (prescription label) section; mycophenolate mofetil's label does not name esomeprazole itself but warns about its class (Proton pump inhibitors (PPIs)). The esomeprazole label: “Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity”
Check it at the source: the esomeprazole FDA label on DailyMed (effective March 19, 2024, Haleon US Holdings LLC); the mycophenolate mofetil FDA label on DailyMed (effective August 5, 2026, Genentech, Inc.).
What does the esomeprazole label say about mycophenolate mofetil?
Esomeprazole label, drug interactions (prescription label)Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF …
Esomeprazole Strontium label (R2 Pharma, LLC, September 22, 2016), drug interactionsLike with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole.
Source: FDA drug label (Esomeprazole Strontium, NDA202342), R2 Pharma, LLC, effective September 22, 2016 (SPL set 3c916d32-f9e9-1d15-e054-00144ff88e88), via openFDA
Source: FDA drug label (Nexium 24HR), NDA204655 (Astrazeneca Lp), as published by Haleon US Holdings LLC, effective March 19, 2024 (SPL set 4513934d-0cf0-40fc-a348-b4e75a33b094), via openFDA; the full label on DailyMed
What does the mycophenolate mofetil label say about esomeprazole?
Mycophenolate mofetil's label does not name esomeprazole itself; it warns about its class (Proton pump inhibitors (PPIs)):
Mycophenolate mofetil label, drug interactionsDRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce CELLCEPT efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. ( 7.1 ) CELLCEPT may reduce effectiveness of oral contraceptives.
Mycophenolate mofetil label, drug interactionsProton Pump Inhibitors (PPIs) Clinical Impact Concomitant use with PPIs decreases MPA systemic exposure [see Clinical Pharmacology (12.3) ], which may reduce CELLCEPT efficacy.
Source: FDA drug label (CellCept), NDA050722 (Roche Palo), as published by Genentech, Inc., effective August 5, 2026 (SPL set 37241e87-4af4-4dc3-a1aa-ea6f20d8dc40), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Esomeprazole | Mycophenolate mofetil | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Organ transplant rejection |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.145 per capsule 20 mg capsule | $0.138 per capsule 250 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once